Saturday 17 October 2026 Export VINC’s income statement to Excel — free account

Vincerx Pharma, Inc.

In the quarter to March 2025, EPS grew 87.9% and free cash flow grew 42.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.02 0.01 −33.33%

Follow VINC

Alert me

Market cap: $250.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.25

Revenue —

Net Income (22.64)

Free Cash Flow (22.84)

Net Debt (4.52)

Current Ratio 1.79

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.03

Past 5Y EPS Growth —

This Y EPS Growth 58.73%

Next Y EPS Growth 23.08%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 15.37%

10-year low 10-year high

EV/FCF against its own 10 years 41.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	Q'25
Cash	53	13	5	5
Receivables	1	1	1	—
Inventory	—	—	—	—
Other	2	1	0	0
	56	15	6	5

	2022	2023	2024	Q'25
Payables	4	2	2	2
ST’ Debt	—	—	—	—
Other	0	0	0	—
	9	6	5	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(69.94%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’24	(8)	(6)	(6)	(6)	(26)
’23	(13)	(13)	(7)	(8)	(40)
’22	(15)	(16)	(15)	(14)	(60)
’21	(3)	(8)	(10)	(11)	(33)
’20	0	0	0	(2)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	—	—	—	—
’24	(8)	(6)	(6)	(6)	(26)
’23	(13)	(13)	(7)	(8)	(40)
’22	(15)	(16)	(15)	(14)	(60)
’22	—	—	—	—	(60)
’21	(8)	(8)	(10)	(11)	(39)
’21	—	—	—	—	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.40)	—	—	—	—
’24	(11.60)	(1.00)	(3.40)	(0.01)	(15.85)
’23	(13.60)	(10.40)	(9.20)	(4.60)	(37.80)
’22	(15.80)	(17.60)	(16.00)	(13.00)	(62.20)
’21	(9.20)	(2.40)	(27.80)	(6.20)	(45.80)
’20	(0.02)	(0.13)	(1.20)	(61.94)	(63.29)
’19	—	—	—	—	(0.20)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	—	—	—	—	187.00	176.40	12.62	12.20	3.50	Analyst estimates 2025–2027 Powerpack
	High	—	—	—	—	—	445.60	535.00	211.20	39.00	187.44
People
People	Employees	—	—	—	—	—	28	56	41	42	13
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	0.00	0.00	—	—
	EBT	—	—	—	—	0	(17)	(39)	(63)	(40)	(30)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	0	—	0	(17)	(39)	(63)	(40)	(30)
	Depreciation	—	—	—	—	—	0	0	1	0	1
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	(0.20)	(63.29)	(45.80)	(62.20)	(37.80)	(15.85)
	Cash flow	—	—	—	—	0.00	(8.68)	(38.89)	(56.68)	(37.98)	(13.77)
	Capex	—	—	—	—	0.00	0.00	(6.12)	0.00	0.00	0.00
	Free cash flow	—	—	—	—	0.00	(8.68)	(45.02)	(56.68)	(37.98)	(13.77)
	Book value	—	—	—	—	(0.20)	96.65	116.82	45.33	10.54	1.44
	Shares, m	—	—	—	—	0	0	1	1	1	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	(2)	(33)	(60)	(40)	(26)
	Capex	—	—	—	—	—	0	(5)	—	—	—
	Free cash flow	—	—	—	—	0	(2)	(39)	(60)	(40)	(26)
Balance, $m
Balance, $m	Working capital	—	—	—	—	0	25	98	47	9	1
	Total debt	—	—	—	—	—	—	4	3	—	—
	Net debt	—	—	—	—	—	(62)	(112)	(53)	(13)	(5)
	Shareholders’ equity	—	—	—	—	0	25	100	48	11	3
Returns, %
Returns, %	ROA	—	—	—	—	(9,000.00)	(52.60)	(43.46)	(71.18)	(103.63)	(229.38)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	103.45	(131.20)	(62.54)	(85.12)	(136.38)	(431.29)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$640.0K	0.0×	— (loss-making)	—	n/m	+51.13% (above 0%: growing)	(228.63%)	(504.50%)	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$440.0K	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
VINC Vincerx Pharma, Inc.	$250.0K	— (loss-making)	—	—	n/m	+42.45% (above 0%: growing)	0.00%	0.00%
CDT CDT Equity Inc.	$240.0K	— (loss-making)	—	—	n/m	+78.92% (above 0%: growing)	—	0.00%	Compare
EFTR eFFECTOR Therapeutics, Inc.	$200.0K	— (loss-making)	—	+58.08% (above 0%: growing)	n/m	+4.86% (above 0%: growing)	0.00%	0.00%	Compare
VRPX Virpax Pharmaceuticals, Inc.	$160.0K	— (loss-making)	—	—	n/m	+4.68% (above 0%: growing)	—	0.00%	Compare
CERO CERo Therapeutics Holdings, Inc.	$140.0K	0.0×	—	—	n/m	+49.65% (above 0%: growing)	—	0.00%	Compare
Median of peers	$340.0K	—	—	+11.90%	—	+27.26%	0.00%	0.00%

All 614 Biotechnology stocks →

Vincerx Pharma, Inc. (VINC) key facts

Vincerx Pharma, Inc. (VINC) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, VINC traded at $0.02, a market capitalization of $250,000.00.
Return on equity was −431.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.